PHARMACY

Kelley-Ross Pharmacy Group promotes 2 pharmacists

BY David Salazar

SEATTLE — Kelley-Ross Pharmacy group announced this week the promotion of two of its pharmacists to new roles. The company named Jeff Kinter the pharmacy manager at its only retail location, the Kelley-Ross Polyclinic, and named Anna Shields its new float pharmacist, both effective June 1.

In his new role, Kinter, a 2015 University of Washington School of Pharmacy graduate, will oversee the retail aspect of the business, including its clinical services team — which includes its Concierge Travel Clinic and One-Step PrEP program — and its pharmacists and technicians. Kinter rose through the Kelley-Ross ranks as its community pharmacy resident, which involved experience in the company’s innovation lab.

“The opportunity to be creative in pharmacy is one of the reasons I enjoy working here,” Kintner said. “I learn something new every day and that sense of always looking for solutions and better ways to serve patients is going to be key to successfully managing the retail side of our business.”

Shields, the current Kelley-Ross community pharmacy resident, graduated in 2016 with her PharmD and MBA from Drake University in Des Moines, Iowa. Her past role focused on medication management in the transitions of care, heart failure and complex regimens settings. In her new role, she will work between Kelley-Ross’ five divisions to support each department’s needs.

“Bringing a perspective of science and business to the table gives me a unique point of view and I’m excited to see how it will apply to a floating role, serving diverse needs of the business,” Shields said.

Kelley-Ross CEO Ryan Oftebro said, “We are excited to have Jeff join our management ranks, and Anna transition from her current role. They are both invaluable assets to our company, and enjoy a very high level of respect  among their peers.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Analyst: An Amazon entry into the pharmacy business would not be ‘market disruptive’

BY Brian Berk

SEATTLE — A Wall Street analyst believes the potential for Amazon’s entry into the pharmacy business would not be “market disruptive.” These are the words of Mizuho Securities analyst Ann Hynes.

According to Barron’s, a major reason for this line of thinking is that ordering drugs by mail is not a new innovation. “CVS and Walgreens have been in this business for years and have relationships with drug companies and insurers that give them an early advantage,” the newspaper wrote.

Amazon “would face major infrastructure, payer and regulatory hurdles,” Hynes noted, with the news source adding “it would also be hard for Amazon to get wider discounts on generic drugs than the current players.”

In addition, many older people would rather go to drug stores than get their drugs by mail, giving an edge to companies with retail locations, the analyst stated. “Mail order penetration has been flat to slightly down over the past five years.”

To read more, click here.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Express Scripts to lower generic costs through Walgreens Boots Alliance Development

BY Michael Johnsen

ST. LOUIS — Express Scripts, through its wholly-owned subsidiary Innovative Product Alignment, on Thursday announced it will participate in the Walgreens Boots Alliance Development group purchasing organization.

"The agreement between Innovative Product Alignment and WBAD will improve supply chain efficiency and advance our ability to help reduce generic prescription drug prices for patients," stated Tim Wentworth, president and CEO, Express Scripts. "Our independent model gives us the flexibility to partner with companies like WBAD to make medicine more affordable and accessible. Econdisc is already extremely competitive today. By gaining access to WBAD through Innovative, we will be better positioned for the future."

In addition, Econdisc Contracting Solutions, a group purchasing organization that contracts with manufacturers to source generic pharmaceuticals on behalf of its participants, will have access to WBAD's sourcing efforts through an arrangement between Econdisc and Innovative Product Alignment. These two organizations will immediately begin developing a transition plan to maximize supply chain efficiencies.

WBAD, based in Bern, Switzerland, is a global group purchasing organization that sources and contracts generic pharmaceuticals on behalf of its members.  With Innovative as a member, WBAD will continue its ongoing efforts to reduce complexity in the global supply chain, both on behalf of its members as well as its manufacturing partners, in order to keep costs lower for patients and clients.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES